| Assay ID | Title | Year | Journal | Article |
|---|
| AID1346728 | Human CB2 receptor (Cannabinoid receptors) | 1997 | Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
| Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. |
| AID1346728 | Human CB2 receptor (Cannabinoid receptors) | 1996 | The Journal of pharmacology and experimental therapeutics, Sep, Volume: 278, Issue:3
| Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. |
| AID1345070 | Human GPR55 (GPR18, GPR55 and GPR119) | 2007 | British journal of pharmacology, Dec, Volume: 152, Issue:7
| The orphan receptor GPR55 is a novel cannabinoid receptor. |
| AID1346701 | Human CB1 receptor (Cannabinoid receptors) | 1995 | Molecular pharmacology, Sep, Volume: 48, Issue:3
| Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. |
| AID1346728 | Human CB2 receptor (Cannabinoid receptors) | 1995 | Molecular pharmacology, Sep, Volume: 48, Issue:3
| Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. |
| AID1346701 | Human CB1 receptor (Cannabinoid receptors) | 1996 | The Journal of pharmacology and experimental therapeutics, Sep, Volume: 278, Issue:3
| Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. |
| AID310545 | Selectivity for human CB2 over human CB1 | 2007 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
| New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. |
| AID127832 | Compound was evaluated in mouse model for cannabimimetic activity, expressed as as effective dose for antinociception (TF) | 1998 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
| Enantioselective synthesis and pharmacology of 11-hydroxy-(1'S,2'R)-dimethylheptyl-delta 8-THC. |
| AID1204172 | Agonist activity at human CB2 receptor transfected in CHO cell membranes after 90 mins by [35S]-GTPgammaS assay | 2015 | European journal of medicinal chemistry, Jun-05, Volume: 97 | New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity. |
| AID607138 | Binding affinity to CB1 receptor | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of endocannabinoid-based chemical probes for the study of cannabinoid receptors. |
| AID1626939 | Induction of CB1-related discriminative stimulus effect in squirrel monkey at 0.003 mg/kg, im measured after 24 hrs | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
| Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues. |
| AID621410 | Displacement of [3H]-CP55940 from human recombinant cannabinoid CB2 receptor expressed in CHO-K1 cells | 2011 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
| Design and evaluation of a novel fluorescent CB2 ligand as probe for receptor visualization in immune cells. |
| AID1626945 | Displacement of [3H]CP55940 from human CB2 receptor | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
| Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues. |
| AID1193635 | Agonist activity at rat cerebellar membrane cannabinoid CB1 receptor assessed as [35S]GTPgammaS binding at 1 uM relative to control | 2015 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
| Loratadine analogues as MAGL inhibitors. |
| AID1193637 | Agonist activity at human cannabinoid CB2 receptor introduced into CHO cells assessed as [35S]GTPgammaS binding at 10 nM relative to control | 2015 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
| Loratadine analogues as MAGL inhibitors. |
| AID259616 | Maximum stimulation at human CB1 receptor by [35S]GTP-gamma-S assay compared to the basal level | 2006 | Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3
| Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists. |
| AID1632066 | Toxicity in naive Sprague-Dawley rat assessed as hypothermia at 0.01 mg/kg, ip after 2 to 48 hrs by core temperature test | 2016 | Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
| Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain. |
| AID310544 | Displacement of [3H]CP-55940 from human recombinant CB2 receptor expressed in HEK293 cells | 2007 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
| New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. |
| AID1626946 | Effect on response rate in squirrel monkey at 0.003 mg/kg, im | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
| Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues. |
| AID259614 | Displacement of [3H]SR141716A from human CB1 receptor | 2006 | Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3
| Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists. |
| AID1416639 | Displacement of [3H]CP55940 from beta-galactosidase reporter fused human CB2 receptor expressed in CHOK1 cell membranes after 1 hr by scintillation spectrometric analysis | 2017 | MedChemComm, Aug-01, Volume: 8, Issue:8
| Bioisosteric replacement of central 1,2,4-oxadiazole ring of high affinity CB |
| AID1632055 | Analgesic activity in naive Sprague-Dawley rat assessed as tail flick latency at 0.1 to 10 mg/kg administered through oral gavage up to 48 hrs by tail-flick assay | 2016 | Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
| Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain. |
| AID1185845 | Displacement of [3H]CP-55,940 from human recombinant CB2 receptor expressed in HEK293 cell membranes | 2014 | Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
| Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist. |
| AID472421 | Antagonist activity at human recombinant alpha 2 GlyR expressed in HEK293 cells assessed as inhibition of glycine current influx by whole cell patch clamp assay | 2010 | Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8
| Ircinialactams: subunit-selective glycine receptor modulators from Australian sponges of the family Irciniidae. |
| AID1626944 | Binding affinity to mouse CB2 receptor | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
| Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues. |
| AID1626941 | Induction of CB1-related discriminative stimulus effect in squirrel monkey at 0.003 mg/kg, im measured at 36 hrs | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
| Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues. |
| AID445959 | Agonist activity at human recombinant cannabinoid CB2 receptor expressed in MMY23 Saccharomyces cerevisiae assessed as degradation of FDGlu to fluorescein after 24 hrs by spectrofluorimetry | 2009 | Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
| Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain. |
| AID1626926 | Hypothermic activity in sc dosed Sprague-Dawley rat assessed as decrease in rectal body temperature measured over 6 hrs | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
| Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues. |
| AID259201 | Effect on [35S]GTP-gamma-S binding to human CB2 receptor | 2006 | Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1
| Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling. |
| AID310543 | Displacement of [3H]CP-55940 from human recombinant CB1 receptor expressed in HEK293 cells | 2007 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
| New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. |
| AID1632065 | Toxicity in naive Sprague-Dawley rat assessed as motor incoordination at 0.01 mg/kg, ip after 2 to 48 hrs by rotarod test | 2016 | Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
| Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain. |
| AID415513 | Binding affinity to human recombinant CB2 receptor expressed in african green monkey COS cells by radioligand binding assay | 2009 | Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
| New resorcinol-anandamide "hybrids" as potent cannabinoid receptor ligands endowed with antinociceptive activity in vivo. |
| AID1127484 | Selectivity ratio of Ki for human CB1 receptor to Ki for human CB2 receptor | 2013 | Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
| Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists. |
| AID1662649 | Displacement of [3H]-CP55940 from human recombinant CB2 receptor expressed in HEK cell membrane | 2020 | Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
| Synthetic bioactive olivetol-related amides: The influence of the phenolic group in cannabinoid receptor activity. |
| AID1057093 | Displacement of [3H]CP-55,940 from human recombinant cannabinoid CB2 receptor expressed in CHO cells | 2013 | Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
| Development of fluorinated CB(2) receptor agonists for PET studies. |
| AID127835 | Compound was evaluated in mouse model for cannabimimetic activity, expressed as effective dose for spontaneous activity(SA) | 1998 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
| Enantioselective synthesis and pharmacology of 11-hydroxy-(1'S,2'R)-dimethylheptyl-delta 8-THC. |
| AID1626938 | Induction of CB1-related discriminative stimulus effect in squirrel monkey assessed as time required for 50% loss of full effect at 0.003 mg/kg, im | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
| Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues. |
| AID1626918 | Half life in mouse plasma assessed as esterase-mediated compound hydrolysis at 200 uM by HPLC method | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
| Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues. |
| AID1632067 | Toxicity in naive Sprague-Dawley rat assessed as immobility at 0.01 mg/kg, ip by after 2 to 48 hrs by catalepsy ring test | 2016 | Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
| Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain. |
| AID1127482 | Binding affinity to human CB1 receptor | 2013 | Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
| Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists. |
| AID1626930 | Hypothermic activity in Sprague-Dawley rat assessed as time required for decrease in rectal body temperature at 0.01 to 1 mg/kg, sc | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
| Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues. |
| AID1416642 | Displacement of [3H]CP55940 from beta-galactosidase reporter fused human CB1 receptor expressed in CHOK1 cell membranes after 1 hr by scintillation spectrometric analysis | 2017 | MedChemComm, Aug-01, Volume: 8, Issue:8
| Bioisosteric replacement of central 1,2,4-oxadiazole ring of high affinity CB |
| AID1245641 | Agonist activity at human CB2R expressed in CHO cell membranes at 10 nM by [35S]GTPgammaS binding assay | 2015 | Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19
| Revisiting 1,3,4-Oxadiazol-2-ones: Utilization in the Development of ABHD6 Inhibitors. |
| AID1632054 | Analgesic activity in naive Sprague-Dawley rat assessed as increase in tail flick latency at 0.3 mg/kg, ip up to 48 hrs by tail-flick assay | 2016 | Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
| Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain. |
| AID257800 | Displacement of [35S]GTP-gamma-S from rat cerebellar CB1 receptor | 2006 | Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
| 3D-QSAR studies on cannabinoid CB1 receptor agonists: G-protein activation as biological data. |
| AID1267177 | Agonist activity at CBR2 (unknown origin) assessed as [35S]GTPgammaS binding at 10 nM by luminescence assay relative to control | 2016 | European journal of medicinal chemistry, Jan-01, Volume: 107 | Potent and selective N-(4-sulfamoylphenyl)thiourea-based GPR55 agonists. |
| AID259615 | Potency at human CB1 receptor in a [35S]GTP-gamma-S functional assay | 2006 | Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3
| Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists. |
| AID1626943 | Binding affinity to rat CB1 receptor | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
| Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues. |
| AID412168 | Agonist activity at human CB2 receptor expressed in yeast cells assessed as degradation of FDGlu to fluorescein after 24 hrs | 2009 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
| Pyridine-3-carboxamides as novel CB(2) agonists for analgesia. |
| AID259200 | Effect on human CB2 receptor stimulation by [35S]GTP-gamma-S binding at 10 uM (basal value set at 100%) | 2006 | Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1
| Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling. |
| AID127834 | Compound was evaluated in mouse model for cannabimimetic activity, expressed as as effective dose for hypothermia (rectal temperature, RT) | 1998 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
| Enantioselective synthesis and pharmacology of 11-hydroxy-(1'S,2'R)-dimethylheptyl-delta 8-THC. |
| AID259197 | Displacement of [3H]CP-55940 from human CB2 receptor | 2006 | Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1
| Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling. |
| AID1245639 | Agonist activity at CB1R in rat cerebellar membranes at 1 uM by [35S]GTPgammaS binding assay | 2015 | Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19
| Revisiting 1,3,4-Oxadiazol-2-ones: Utilization in the Development of ABHD6 Inhibitors. |
| AID445957 | Agonist activity at human recombinant cannabinoid CB1 receptor expressed in MMY23 Saccharomyces cerevisiae assessed as degradation of FDGlu to fluorescein after 24 hrs by spectrofluorimetry | 2009 | Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
| Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain. |
| AID288422 | Agonist activity at human recombinant CB2 receptor expressed in Saccharomyces cerevisiae cells | 2007 | Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
| Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. |
| AID1433080 | Hypothermic activity in sc dosed Sprague-Dawley rat assessed as duration of hypothermic effect at 0.3 mg/kg, sc measured after 12 hrs post dose | 2015 | Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
| Probing the carboxyester side chain in controlled deactivation (-)-δ(8)-tetrahydrocannabinols. |
| AID474948 | Antagonist activity at human recombinant alpha 1 GlyR expressed in HEK293 cells assessed as inhibition of glycine current influx by whole cell patch clamp assay | 2010 | Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8
| Ircinialactams: subunit-selective glycine receptor modulators from Australian sponges of the family Irciniidae. |
| AID1433075 | Hypothermic activity in sc dosed Sprague-Dawley rat measured over 6 hrs post dose | 2015 | Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
| Probing the carboxyester side chain in controlled deactivation (-)-δ(8)-tetrahydrocannabinols. |
| AID49666 | Displacement of [3H]CP-55940 binding to Cannabinoid receptor 1 in rat brain membranes | 1998 | Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
| Derivation of a pharmacophore model for anandamide using constrained conformational searching and comparative molecular field analysis. |
| AID1626937 | Induction of CB1-related discriminative stimulus effect in squirrel monkey at 0.003 mg/kg, im measured within 15 mins | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
| Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues. |
| AID472422 | Antagonist activity at human recombinant alpha 1 GlyR expressed in HEK293 cells assessed as inhibition of glycine current influx up to 30 uM by whole cell patch clamp assay | 2010 | Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8
| Ircinialactams: subunit-selective glycine receptor modulators from Australian sponges of the family Irciniidae. |
| AID1127483 | Binding affinity to human CB2 receptor | 2013 | Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
| Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists. |
| AID416057 | Displacement of [3H]CP-55940 form human recombinant CB1 receptor expressed in HEK293 cells by liquid scintillation counting | 2009 | European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
| Analogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): development of ligands with optimized lipophilicity and binding affinity. |
| AID259617 | Displacement of [3H]SR141716A from CB1 receptor in rat cerebellum | 2006 | Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3
| Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists. |
| AID49146 | Binding affinity for the Cannabinoid receptor using [3H]CP-55940 as radioligand | 1998 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
| Enantioselective synthesis and pharmacology of 11-hydroxy-(1'S,2'R)-dimethylheptyl-delta 8-THC. |
| AID288424 | Agonist activity at human recombinant CB1 receptor expressed in Saccharomyces cerevisiae cells upto 30 uM | 2007 | Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
| Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. |
| AID1626919 | Half life in rat plasma assessed as esterase-mediated compound hydrolysis at 200 uM by HPLC method | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
| Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues. |
| AID1632064 | Analgesic activity in naive Sprague-Dawley rat assessed as tail flick latency at 0.01 mg/kg, ip up to 48 hrs by tail-flick assay | 2016 | Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
| Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain. |
| AID1802031 | FABP1 Fluorescent Ligand Displacement Assay from Article 10.1021/acs.biochem.6b00446: \\FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein.\\ | 2016 | Biochemistry, 09-20, Volume: 55, Issue:37
| FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |